In a previous study we reported that the selective pressure of tamoxifen leads to activation of NFκB in patients treated with neoadjuvant tamoxifen, as well as in breast cancer cell lines and xenograft tumors [17]. The gene discussed is NFKB1; the disease is breast carcinoma.